New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk

Archives of Internal Medicine

Volumn 169, Issue 18, 2009, Pages 1684-1691

  Crandall, Carolyn J ^a   Aragaki, Aaron K ^b   Chlebowski, Rowan T ^c   McTiernan, Anne ^b   Anderson, Garnet ^b   Hendrix, Susan L ^d   Cochrane, Barbara B ^e   Kuller, Lewis H ^f   Cauley, Jane A ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST EXAMINATION; BREAST TENDERNESS; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MEDICAL RECORD REVIEW; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT;

AGED; BREAST; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; PAIN; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; SENSITIVITY AND SPECIFICITY;

EID: 70350042203     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.303     Document Type: Article

References (45)

1. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
2. Chlebowski RT, Hendrix SL, Langer RD, et al; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003; 289(24):3243-3253. (Pubitemid 37430077)
3. Crandall CJ, Karlamangla A, Huang MH, Ursin G, Guan M, Greendale GA. Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy [published correction appears in Arch Intern Med. 2006 Nov 13;166(20):2176]. Arch Intern Med. 2006;166(15):1578-1584.
4. Barnabei VM, Cochrane BB, Aragaki AK, et al; Women's Health Initiative Investigators. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol. 2005;105(5, pt 1): 1063-1073.
5. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;75(6):1065-1079. (Pubitemid 32522600)
6. Bülbül NH, Özden S, Dayicioglu V. Effects of hormone replacement therapy on mammographic findings. Arch Gynecol Obstet. 2003;268(1):5-8. (Pubitemid 36717860)
7. McNicholasMM,Heneghan JP, MilnerMH,Tunney T, Hourihane JB, MacErlaine DP. Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study. AJR Am J Roentgenol. 1994;163(2):311-315.
8. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst. 1995;87(9):670-675.
9. Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19(1):61-109.
10. Ritenbaugh C, Patterson RE, Chlebowski RT, et al. The Women's Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. Ann Epidemiol. 2003;13(9)(suppl):S87-S97. (Pubitemid 37324178)
11. Curb JD, McTiernan A, Heckbert SR, et al; WHI Morbidity and Mortality Committee. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol. 2003;13(9)(suppl):S122-S128.
12. Ganz PA, Day R, Ware JE Jr, Redmond C, Fisher B. Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst. 1995;87(18):1372- 1382.
13. Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/ Progestin Interventions Trial. Obstet Gynecol. 1998;92(6):982-988. (Pubitemid 28536116)
14. Chlebowski RT, Anderson GL, Lane DS, et al; Women's Health Initiative Investigators. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst. 2007;99(22):1695-1705.
15. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999; 91(18):1541-1548. (Pubitemid 29457958)
16. Gapstur SM, López P, Colangelo LA, Wolfman J, Van Horn L, Hendrick RE. Associations of breast cancer risk factors with breast density in Hispanic women. Cancer Epidemiol Biomarkers Prev. 2003;12(10):1074-1080. (Pubitemid 37310265)
17. Riza E, dos Santos Silva I, De Stavola B, et al. Correlates of high-density mammographic parenchymal patterns by menopausal status in a rural population in Northern Greece. Eur J Cancer. 2005;41(4):590-600.
18. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst. 2003;95(1):30-37. (Pubitemid 36124293)
19. Masala G, Ambrogetti D, Assedi M, Giorgi D, Del Turco MR, Palli D. Dietary and lifestyle determinants of mammographic breast density: a longitudinal study in a Mediterranean population. Int J Cancer. 2006;118(7):1782-1789. (Pubitemid 43376444)
20. López P, Van Horn L, Colangelo LA, Wolfman JA, Hendrick RE, Gapstur SM. Physical inactivity and percent breast density among Hispanic women. Int J Cancer. 2003;107(6):1012-1016. (Pubitemid 37429844)
21. Maskarinec G, Pagano I, Chen Z, Nagata C, Gram IT. Ethnic and geographic differences in mammographic density and their association with breast cancer incidence. Breast Cancer Res Treat. 2007;104(1):47-56. (Pubitemid 46976628)
22. Rubin DB. Multiple imputation after 18+years. J Am Stat Assoc. 1996;91(434): 473-489.
23. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8(4):431-440. (Pubitemid 19105891)
24. Li Z, Meredith MP, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med. 2001;20(21):3175-3188. (Pubitemid 33034879)
25. American Cancer Society. Breast Cancer Facts & Figures 2007-2008. Atlanta, GA: American Cancer Society; 2007.
26. Bright RA, Morrison AS, Brisson J, et al. Relationship between mammographic and histologic features of breast tissue in women with benign biopsies. Cancer. 1988;61(2):266-271. (Pubitemid 18056481)
27. Wellings SR, Wolfe JN. Correlative studies of the histological and radiographic appearance of the breast parenchyma. Radiology. 1978;129(2):299-306.
28. Conner P, Söderqvist G, Skoog L, et al. Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology. Breast Cancer Res Treat. 2003;78(2):159-165.
29. Conner P, Christow A, Kersemaekers W, et al. A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolon and continuous combined estrogen-progestogen treatment. Climacteric. 2004;7(1):50-58. (Pubitemid 38367163)
30. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab. 1999;84(12):4559-4565.
31. Boyd NF, Martin LJ, Li Q, et al. Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(5):961-966. (Pubitemid 43823524)
32. Ursin G, Palla SL, Reboussin BA, et al. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Clin Oncol. 2004;22(14):2842-2848. (Pubitemid 41079902)
33. Crandall CJ, Guan M, Laughlin GA, et al. Increases in serum estrone sulfate level are associated with increased mammographic density during menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1674-1681.
34. Cuzick J, Sestak I, Cella D, Fallowfield L; ATAC Trialists' Group. Treatmentemergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol. 2008;9(12):1143-1148.
35. Akhila V, Pratapkumar. A comparison of transdermal and oral HRT for menopausal symptom control. Int J Fertil Womens Med. 2006;51(2):64-69.
36. Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab. 2007;92(3):911-918.
37. Carranza-Lira S, Garduño-Hernández MP, Caisapanta DA, Aparicio H. Evaluation of mastodynia in postmenopausal women taking hormone therapy. Int J Gynaecol Obstet. 2005;89(2):158-159. (Pubitemid 40585623)
38. Chen LC, Tsao YT, Yen KY, Chen YF, Chou MH, Lin MF. A pilot study comparing the clinical effects of Jia-Wey Shiau-Yau San, a traditional Chinese herbal prescription, and a continuous combined hormone replacement therapy in postmenopausalwomen with climacteric symptoms. Maturitas. 2003;44(1):55-62.
39. Jackson VP, San Martin JA, Secrest RJ, et al. Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women [published correction appears in Am J Obstet Gynecol. 2003 Jun;188(6):1628]. Am J Obstet Gynecol. 2003 Feb;188(2):389-394.
40. Simon JA, Liu JH, Speroff L, Shumel BS, Symons JP. Reduced vaginal bleeding in postmenopausalwomenwhoreceivecombinednorethindrone acetateandlow-dose ethinyl estradiol therapy versuscombinedconjugated equine estrogensandmedroxyprogesterone acetate therapy. Am J Obstet Gynecol. 2003;188(1):92-99. (Pubitemid 36135603)
41. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93(5):358-366. (Pubitemid 32229380)
42. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med. 1998;338(16):1089-1096. (Pubitemid 28227478)
43. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas. 2006;55(2):103-115. (Pubitemid 44307491)
44. McTiernan A, Martin CF, Peck JD, et al; Women's Health Initiative Mammogram Density Study Investigators. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst. 2005;97(18):1366-1376.
45. Chlebowski RT, Anderson G, Pettinger M, et al; Women's Health Initiative Investigators. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy [published correction appears in Arch Intern Med. 2008;12;168(9):935]. Arch Intern Med. 2008;168(4):370-377, quiz 345.